Arecor partnership with biopharmaceutical company
Arecor establishes formulation development partnership with biopharmaceutical company on peptide therapy using Arestat technology.
- Global peptide therapeutics market projection more than $100 billion by 2034
- Projected CAGR 10.8%
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
- Partner to fund development work with option to acquire rights to proprietary formulation under Arecor's technology licensing model
Cambridge, UK, 12 March 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces a formulation development collaboration with a clinical-stage biopharmaceutical company developing peptide therapies. The partnership aims to develop a differentiated formulation of the partner's peptide therapy using Arecor's proprietary formulation technology platform, Arestat™. The collaboration reinforces Arecor's expertise developing novel formulations of peptide therapeutics.
Under the terms of the agreement, the partner will fund Arecor's development activities with the option to license rights to the new proprietary formulation and associated intellectual property to further develop and commercialise the product.
Arecor has an excellent track record developing challenging therapeutic peptide product profiles using its Arestat™ technology. Within the Company's broader product portfolio, Arecor continues to progress the potential of its Arestat™ platform to enable oral peptide delivery, through its initial oral glucagon-like peptide-1 (GLP-1) receptor agonist programme.
The global peptide therapeutics market is projected to reach more than $100 billion by 2034 growing at a CAGR of 10.8% 1, driven by peptide therapeutics' strong efficacy and selectivity towards different receptors on target cells, the rise of endocrine and metabolic diseases, and technological advancements in the field.
Sarah Howell, Chief Executive Officer of Arecor, said: "Peptides are an increasingly important class of therapeutics to treat a wide range of chronic conditions. Arecor has significant expertise in developing novel formulations of therapeutic peptides to address unmet patient needs in this large and growing market. This collaboration further validates our leadership in this field."
References
- Future Market Insights: Peptide Therapeutics Market Outlook from 2024 to 2034
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.